Astellas Pharma Stock Fundamentals
| ALPMF Stock | USD 10.00 0.30 3.09% |
Astellas Pharma fundamentals help investors to digest information that contributes to Astellas Pharma's financial success or failures. It also enables traders to predict the movement of Astellas Pink Sheet. The fundamental analysis module provides a way to measure Astellas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Astellas Pharma pink sheet.
Astellas |
Astellas Pharma Company Current Valuation Analysis
Astellas Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Astellas Pharma Current Valuation | 26.19 B |
Most of Astellas Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Astellas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Astellas Pharma has a Current Valuation of 26.19 B. This is 82.32% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all United States stocks is 57.52% lower than that of the firm.
Astellas Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Astellas Pharma's current stock value. Our valuation model uses many indicators to compare Astellas Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Astellas Pharma competition to find correlations between indicators driving Astellas Pharma's intrinsic value. More Info.Astellas Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Astellas Pharma is roughly 1.38 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Astellas Pharma's earnings, one of the primary drivers of an investment's value.Astellas Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astellas Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics of similar companies.Astellas Pharma is currently under evaluation in current valuation category among its peers.
Astellas Fundamentals
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.43 % | |||
| Price To Earning | 25.09 X | |||
| Price To Book | 2.38 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 241.52 B | |||
| Net Income | 124.09 B | |||
| Cash And Equivalents | 336.76 B | |||
| Cash Per Share | 184.77 X | |||
| Total Debt | 4.87 B | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 1.34 X | |||
| Book Value Per Share | 861.58 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.57 X | |||
| Target Price | 50.0 | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 26.66 B | |||
| Total Asset | 2.33 T | |||
| Retained Earnings | 941.23 B | |||
| Working Capital | 491.17 B | |||
| Current Asset | 874.69 B | |||
| Current Liabilities | 383.53 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.25 % | |||
| Net Asset | 2.33 T | |||
| Last Dividend Paid | 25.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Pink Sheet
Astellas Pharma financial ratios help investors to determine whether Astellas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.